210 related articles for article (PubMed ID: 36809990)
1. Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.
De Castro J; Insa A; Collado-Borrell R; Escudero-Vilaplana V; Martínez A; Fernandez E; Sullivan I; Arrabal N; Carcedo D; Manzaneque A
BMC Pulm Med; 2023 Feb; 23(1):69. PubMed ID: 36809990
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel.
Isla D; González-Rojas N; Nieves D; Brosa M; Finnern HW
Clin Transl Oncol; 2011 Jul; 13(7):460-71. PubMed ID: 21775273
[TBL] [Abstract][Full Text] [Related]
4. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
Wood R; Taylor-Stokes G
BMC Cancer; 2019 Mar; 19(1):214. PubMed ID: 30849964
[TBL] [Abstract][Full Text] [Related]
5. Economic Burden of Recurrence in Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer: A Retrospective Study Using Nationwide Claims Data of South Korea.
Byun JY; Lee JE; Shim YB; Kim J; Lee SY; Shin BR; Yoon NR; Park MH; Lee EK
Adv Ther; 2023 Feb; 40(2):550-567. PubMed ID: 36404368
[TBL] [Abstract][Full Text] [Related]
6. The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States.
Sieluk J; Song Y; Freimark J; Huang M; Haiderali A; Berman R; Wang T; Signorovitch J; Hirshfield KM
Adv Ther; 2022 Feb; 39(2):943-958. PubMed ID: 34918193
[TBL] [Abstract][Full Text] [Related]
7. [The costs of a multiple sclerosis relapse in Catalonia (Spain)].
Casado V; Martinez-Yelamos S; Martinez-Yelamos A; Carmona O; Alonso L; Romero L; Moral E; Arbizu T
Neurologia; 2006 Sep; 21(7):341-7. PubMed ID: 16977554
[TBL] [Abstract][Full Text] [Related]
8. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
9. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
10. The economic burden of disease of epithelial ovarian cancer in Spain: the OvarCost study.
Delgado-Ortega L; González-Domínguez A; Borrás JM; Oliva-Moreno J; González-Haba E; Menjón S; Pérez P; Vicente D; Cordero L; Jiménez M; Simón S; Hidalgo-Vega Á; Moya-Alarcón C
Eur J Health Econ; 2019 Feb; 20(1):135-147. PubMed ID: 29922900
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
Migliorino MR; Santo A; Romano G; Cortinovis D; Galetta D; Alabiso O; Cartenì G; Vari S; Fasola G; Pazzola A; Giuffrida D; Zaniboni A; Caprioli A; Longo F; Acciai V; de Marinis F
J Cancer Res Clin Oncol; 2017 May; 143(5):783-791. PubMed ID: 28215027
[TBL] [Abstract][Full Text] [Related]
12. Estimation of lung cancer diagnosis and treatment costs based on a patient-level analysis in Catalonia (Spain).
Corral J; Espinàs JA; Cots F; Pareja L; Solà J; Font R; Borràs JM
BMC Health Serv Res; 2015 Feb; 15():70. PubMed ID: 25889153
[TBL] [Abstract][Full Text] [Related]
13. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
[TBL] [Abstract][Full Text] [Related]
14. The economic burden of pulmonary arterial hypertension in Spain.
Zozaya N; Abdalla F; Casado Moreno I; Crespo-Diz C; Ramírez Gallardo AM; Rueda Soriano J; Alcalá Galán M; Hidalgo-Vega Á
BMC Pulm Med; 2022 Mar; 22(1):105. PubMed ID: 35346140
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic approaches to lung cancer in Canada and their costs.
Evans WK; Will BP; Berthelot JM; Wolfson MC
Br J Cancer; 1995 Nov; 72(5):1270-7. PubMed ID: 7577481
[TBL] [Abstract][Full Text] [Related]
16. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
[TBL] [Abstract][Full Text] [Related]
17. Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs.
Apple J; DerSarkissian M; Shah A; Chang R; Chen Y; He X; Chun J
J Comp Eff Res; 2023 Nov; 12(11):e230107. PubMed ID: 37655686
[No Abstract] [Full Text] [Related]
18. Estimated direct costs of non-small cell lung cancer by stage at diagnosis and disease management phase: A whole-disease model.
Buja A; Rivera M; De Polo A; Brino ED; Marchetti M; Scioni M; Pasello G; Bortolami A; Rebba V; Schiavon M; Calabrese F; Mandoliti G; Baldo V; Conte P
Thorac Cancer; 2021 Jan; 12(1):13-20. PubMed ID: 33219738
[TBL] [Abstract][Full Text] [Related]
19. Changing costs of metastatic non small cell lung cancer in the Netherlands.
Keusters WR; de Weger VA; Hövels A; Schellens JHM; Frederix GWJ
Lung Cancer; 2017 Dec; 114():56-61. PubMed ID: 29173766
[TBL] [Abstract][Full Text] [Related]
20. Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
Nadal E; Bautista D; Cabezón-Gutiérrez L; Ortega AL; Torres H; Carcedo D; Ruiz de Alda L; Garcia JF; Vieitez P; Rojo F
BMC Cancer; 2021 Jun; 21(1):689. PubMed ID: 34112097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
